$100 million NuvaRing settlement finalized

A $100 million settlement involving NuvaRing, a birth-control device linked to sometimes-fatal side effects, will stand now that enough claimants have chosen to opt into the agreement.

U.S. District Judge Rodney W. Sippel of St. Louis approved the in February, but NuvaRing maker Merck & Co. had the right to abandon the deal if less than 95 percent of claimants opted in.

Attorneys for the claimants and Merck said Thursday that the 95 percent threshold has been reached. St. Louis attorney Roger Denton, lead lawyer for those who sued, says about 3,800 claimants will share in the settlement.

The lawsuits allege faulty design and testing, and claim that potential hazards of the device were not adequately disclosed.

Merck says there is "substantial" evidence to show that NuvaRing is safe.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Germany's Merck to buy materials supplier AZ

Dec 05, 2013

Germany's Merck KGaA has announced plans to buy AZ Electronic Materials, which supplies high-tech materials for the electronics industry, for about 1.6 billion pounds ($2.6 billion).

Recommended for you

Why aren't there any human doctors in Star Wars?

Jan 30, 2015

Though set "a long time ago in a galaxy far, far away," it isn't hard to see in the Star Wars films a vision of our own not so distant future. But Anthony Jones, a physician with a long background in health ...

Cambodia bans 'virgin surgery' adverts

Jan 29, 2015

The Cambodian government has ordered a hospital to stop advertising so-called virginity restoration procedures, saying it harms the "morality" of society.

What's happening with your donated specimen?

Jan 28, 2015

When donating blood, plasma, human tissue or any other bodily sample for medical research, most people might not think about how it's being used. But if you were told, would you care?

Amgen tops Street 4Q forecasts

Jan 27, 2015

Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.